J A N U A R Y 2 0 2 3
WRITING THE FUTURE
Legal Disclaimers
This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, financial guidance for fiscal 2023 and 2024 and the first quarter of fiscal 2023, statements regarding future growth, expansion, market share gains, plans to achieve adjusted EBITDA break-even for Twist's core business and biopharma and Twist Bioscience's other expectations regarding its future operations plans and financial performance, expected commencement of product shipment from the "Factory of the Future" in January 2023; timing of the early access launch of Twist Bioscience's first DNA data storage solution, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies, including Abveris, and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 28, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
2 T w i s t B i o s c i e n c e
W R I T I N G T H E F U T U R E O N E D N A S T R A N D AT A T I M E
C e l l t h e r a p y | D a t a s t o r a g e | ||||||||
E n z y m e e n g i n e e r i n g | P r o t e i n e n g i n e e r i n g | ||||||||
S t r u c t u r a l g e n o m i c s | M i n i m a l r e s i d u a l d i s e a s e | A g r i g e n o m i c s | |||||||
G e n e a l o g y | L i q u i d b i o p s y | G l o b a l f o o d s e c u r i t y | C a r b o n r e c y c l i n g | ||||||
H e r e d i t a r y t e s t i n g | C a n c e r t e s t i n g | G e n e t h e r a p y | P e r s o n a l i z e d m e d i c i n e | ||||||
P o p u l a t i o n g e n e t i c s | F o r e n s i c s | A n t i b o d y t h e r a p e u t i c s | V a c c i n e d e v e l o p m e n t | ||||||
G e n e t i c s c r e e n i n g | R a r e d i s e a s e t e s t i n g | N u t r i t i o n | A n i m a l h e a l t h | ||||||
G l o b a l f o o d s e c u r i t y | P a t h o g e n s u r v e i l l a n c e | P r o t e i n d e g r a d a t i o n | |||||||
A n c i e n t D N A | N e u r o s c i e n c e | T a r g e t D i s c o v e r y | I n f e c t i o u s d i s e a s e | M i c r o b i o l o g y | |||||
M a t e r i a l s c i e n c e | T r a n s l a t i o n a l r e s e a r c h | I n d u s t r i a l c h e m i c a l i n g r e d i e n t s |
D N A . R N A . P R O T E I N S .
3 T w i s t B i o s c i e n c e
For Research Use Only. Not for use in diagnostic procedures
Twist is:
I N N O VAT I O N
COMMERCIAL EXECUTION
PATH TO PROFITABILITY
4 T w i s t B i o s c i e n c e
Twist DNA Writing on Silicon Platform
Everyone Else
1 oligo per well | 1M oligos per chip |
Up to | ||
10,000X | ||
96 Well Plate | Twist Silicon Platform | more scale |
& throughput | ||
makes 1 gene | can make 9,600 genes |
5 T w i s t B i o s c i e n c e
State of the art
commercial
infrastructure
Proprietary SW powering:
Integrated
eCommerce platform Custom instruments
Manufacturing execution system
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Twist Bioscience Corporation published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 14:18:05 UTC.